Bordeaux Cedex 09, France
French Lumbar Total Disk Replacement Observational Study
Secondary objectives: The secondary objectives are: - Describe the reasons for re-interventions operated floor and / or (x) level (s) adjacent (s) - Describe the evolution of the function with the functional Oswestry score - Describe the evolution of lumbar radicular pain by visual analog scale (VAS) - Describe the evolution of the quality of life assessed by the SF12 score - Describe the evolution of work status - Describe patient satisfaction - Describe the complications (intraoperative, early postoperative (within 3 months of surgery), late, death)
Phase
N/ASpan
344 weeksSponsor
Medtronic France SASMerignac
Recruiting
Prospective Randomized Study Comparing the SpheriKA® (MEDACTA) and Origin® (SYMBIOS) Prostheses During Total Knee Replacement Using the Kinematic Alignment Technique
Phase
N/ASpan
187 weeksSponsor
Clinique du Sport, Bordeaux MérignacMerignac
Recruiting
Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France
This is a non-interventional, prospective (primary data), multicenter study conducted in metropolitan France. The primary objective of this study is to describe the quality of life of MS patients after initiation of treatment with ofatumumab. In order to form a representative sample of MS patients taking into account the terms of care in France, free or practicing neurologists in healthcare institutions (public or private) in different regions of France will be selected to participate in this study. The study will enroll adult patients with MS who initiated ofatumumab according to the physician's advice and independently of the study. Patients will be followed from initiation of ofatumumab either until (i) 12 months (± 1month) after initiation of ofatumumab (End of Study), or until (ii) discontinuation of treatment with ofatumumab prior to the completion of the 12-month follow-up (early termination); whichever occurs first (end of study or early termination).
Phase
N/ASpan
137 weeksSponsor
Novartis PharmaceuticalsLe Bouscat
Recruiting